A Phase 2/3 interventional study of Zavegepant (BHV-3500) in Acute Migraine, sponsored by Pfizer. Completed at 67 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-18.
Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing zavegepant in Migraine Disorders — 4 open to participants now, 4 under way, none of them phase 3. zavegepant · Migraine Disorders.
Among the 12 studies testing zavegepant in Migraine Disorders, this one is the 5th largest by enrollment, is one of 2 that started in 2020, is one of 3 in phase 2/3, and was the 2nd registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →4 of the 12 studies testing zavegepant in Migraine Disorders are open now, in 1 country. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in United States
Ages 6–11
Mayo Clinic · Sites in United States
Ages 18+
American Center for Psychiatry and Neurology
Ages 18+
By country, each count listing its studies:
zavegepant: first FDA approval 2023 (ZAVZPRET). What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 6 · Phase 4 2
First in 2019; this study’s year is marked. 2 started in 2020.
This study's enrollment of 974 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 225 across the 12 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 12 have an industry lead sponsor. The 5 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
47 studies in Migraine Disorders by Pfizer: 10 open now, 14 under way, 6 of them phase 3. Of 30 finished, 24 (80%) have results posted.
Among the 47 studies in Migraine Disorders by Pfizer, this one is the 14th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2020, is one of 5 in phase 2/3, and was the 14th registered.
Pfizer’s Migraine Disorders studies by the year they started, since 2007.
3 of the studies testing zavegepant in Migraine Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06401642Mayo ClinicEffectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications | 2027-03 |
| NCT07667621University of South FloridaA Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department | 2027-07 |
| NCT06995729PfizerA Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine | 2027-08-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies testing zavegepant in Migraine Disorders, from their registry updates:
Among Pfizer’s 47 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term safety of BHV-3500/vazegepant intranasal in the acute treatment of migraine.
* BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant). The World Health Organization (WHO) International Nonproprietary Names (INN) Expert Committee revised the name to "zavegepant" which was accepted by the United States Adopted Names (USAN ) Council for use in the U.S. and is pending formal adoption by the INN for international use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mg intranasal (IN) up to 8 times per month, up to 1 year
Drug: Zavegepant (BHV-3500)
10 mg IN up to 8 times per month, up to 1 year
Also known as: Vazegepant
Number Of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading To Discontinuation
An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in participants or clinical investigation participants administered an investigational (medicinal) product that does not necessarily have a causal relationship with this treatment. An SAE was defined as any event that met any of the following criteria at any dose: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant who received study drug; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the other serious outcomes.
Time frame: From study drug dosing up to the end of the study (up to 52 weeks)
Number Of Participants With Clinically Significant Laboratory Abnormalities
Clinically significant laboratory abnormalities were defined as Grades 3 to 4 laboratory test results according to numeric laboratory test criteria found in Common Technical Criteria for Adverse Events Version 5.0 (2017) if available; otherwise, according to Division of Acquired Immune Deficiency Syndrome. Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 (2017) for glucose, low-density lipoprotein (LDL)-cholesterol, uric acid, and urinalysis. Laboratory test groups of clinical interest included hematology, serum chemistry, and urinalysis. Participants must have had a non-missing measurement in to be included for a given parameter. Laboratory results were presented in US units.
Time frame: From study drug dosing up to the end of the study (up to 52 weeks)
The study was conducted at 63 sites in the United States.
| Milestone | Zavegepant 10 mg |
|---|---|
| Started | 608 |
| Treated/safety analysis set | 603 |
| Completed | 341 |
| Not completed | 267 |
| Withdrew: Adverse event | 43 |
| Withdrew: Infrequent study drug usage | 43 |
| Withdrew: Lack of efficacy | 61 |
| Withdrew: Lost to follow-up | 33 |
| Withdrew: Non-compliance | 6 |
| Withdrew: Physician decision | 1 |
| Withdrew: Pregnancy | 6 |
| Withdrew: Protocol deviation | 9 |
| Withdrew: Sheehan-sts result | 1 |
| Withdrew: Withdrawal by subject | 57 |
| Withdrew: Terminated study prematurely due to covid-19 - adverse event | 2 |
| Withdrew: Never treated migraine | 5 |
An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in participants or clinical investigation participants administered an investigational (medicinal) product that does not necessarily have a causal relationship with this treatment. An SAE was defined as any event that met any of the following criteria at any dose: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant who received study drug; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention to prevent one of the other serious outcomes.
| Participants | Zavegepant 10 mg |
|---|---|
| AEs | 460 |
| SAEs | 7 |
| AEs leading to discontinuation | 41 |
Clinically significant laboratory abnormalities were defined as Grades 3 to 4 laboratory test results according to numeric laboratory test criteria found in Common Technical Criteria for Adverse Events Version 5.0 (2017) if available; otherwise, according to Division of Acquired Immune Deficiency Syndrome. Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 (2017) for glucose, low-density lipoprotein (LDL)-cholesterol, uric acid, and urinalysis. Laboratory test groups of clinical interest included hematology, serum chemistry, and urinalysis. Participants must have had a non-missing measurement in to be included for a given parameter. Laboratory results were presented in US units.
| Participants | Zavegepant 10 mg |
|---|---|
| Alanine Aminotransferase | 3 |
| Aspartate Aminotransferase | 5 |
| Albumin | 0 |
| Alkaline Phosphatase | 0 |
| Bicarbonate | 0 |
| Biliburin | 0 |
| Calcium, low | 0 |
| Calcium, high | 0 |
| Cholesterol | 0 |
| Creatine Kinase (All Methods) | 13 |
| Creatine Kinase | 13 |
| Creatinine | 0 |
| Glomerular Filtration Rate, Estimated | 0 |
| LDL-cholesterol | 21 |
| LDL-cholesterol, fasting | 6 |
| LDL-cholesterol, not fasting | 15 |
| Lactate Dehydrogenase | 0 |
| Potassium, low | 0 |
| Potassium, high | 1 |
| Sodium, low | 0 |
| Sodium, high | 0 |
| Triglycerides | 1 |
| Triglycerides, fasting | 0 |
| Triglycerides, not fasting | 1 |
| Uric Acid | 0 |
| Eosinophils | 0 |
| Hemoglobin | 0 |
| Lymphocytes, low | 0 |
| Lymphocytes, high | 0 |
| Neutrophils | 2 |
| Platelets | 0 |
| White Blood Cells | 0 |
| Qualitative Glucose | 0 |
| Qualitative Protein | 0 |
| Urine Erythrocytes | 0 |
Collected over From study drug dosing up to the end of the study (up to 52 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zavegepant 10 mg | 0/603 (0%) | 7/603 (1.2%) | 336/603 (55.7%) |
| Event | Zavegepant 10 mg |
|---|---|
| AppendicitisInfections and infestations | 1/603 |
| Herpes zoster meningoencephalitisInfections and infestations | 1/603 |
| PneumoniaInfections and infestations | 1/603 |
| Bile duct stenosisHepatobiliary disorders | 1/603 |
| ConcussionInjury, poisoning and procedural complications | 1/603 |
| FallInjury, poisoning and procedural complications | 1/603 |
| Back painMusculoskeletal and connective tissue disorders | 1/603 |
| Multiple sclerosisNervous system disorders | 1/603 |
| PleurisyRespiratory, thoracic and mediastinal disorders | 1/603 |
| Event | Zavegepant 10 mg |
|---|---|
| DysgeusiaNervous system disorders | 236/603 |
| Nasal discomfortRespiratory, thoracic and mediastinal disorders | 62/603 |
| COVID-19Infections and infestations | 45/603 |
| NauseaGastrointestinal disorders | 37/603 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 33/603 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 33/603 |
| Back painMusculoskeletal and connective tissue disorders | 33/603 |
Safety analysis set included participants in the enrolled analysis set who took the study drug, that is, non-missing study drug start date/time.
| Age, Continuous(years) | Zavegepant 10 mg |
|---|---|
| Mean | 42.1 ± 12.46 |
| Sex: Female, Male(Participants) | Zavegepant 10 mg |
|---|---|
| Female | 517 |
| Male | 86 |
| Ethnicity (NIH/OMB)(Participants) | Zavegepant 10 mg |
|---|---|
| Hispanic or Latino | 71 |
| Not Hispanic or Latino | 532 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Zavegepant 10 mg |
|---|---|
| American Indian or Alaska Native | 2 |
| Asian | 23 |
| Native Hawaiian or Other Pacific Islander | 2 |
| Black or African American | 70 |
| White | 502 |
| More than one race | 4 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2020 to primary completion in Dec 2021, 17 months.
Results were first posted in Mar 2023, 1 year 3 months after primary completion. A results delay was requested in Sep 2022.
Of 12 phase 2/3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 17 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zavegepant